RU2008121750A - Ионофоретическая доставка ротиготина для лечения болезни паркинсона - Google Patents
Ионофоретическая доставка ротиготина для лечения болезни паркинсона Download PDFInfo
- Publication number
- RU2008121750A RU2008121750A RU2008121750/15A RU2008121750A RU2008121750A RU 2008121750 A RU2008121750 A RU 2008121750A RU 2008121750/15 A RU2008121750/15 A RU 2008121750/15A RU 2008121750 A RU2008121750 A RU 2008121750A RU 2008121750 A RU2008121750 A RU 2008121750A
- Authority
- RU
- Russia
- Prior art keywords
- chloride
- concentration
- rotigotine
- use according
- composition
- Prior art date
Links
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims abstract 11
- 229960003179 rotigotine Drugs 0.000 title claims abstract 11
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract 5
- 238000001962 electrophoresis Methods 0.000 title 1
- 230000002154 ionophoretic effect Effects 0.000 title 1
- 150000003841 chloride salts Chemical class 0.000 claims abstract 10
- KLBOFRLEHJAXIU-UHFFFAOYSA-N tributylazanium;chloride Chemical compound Cl.CCCCN(CCCC)CCCC KLBOFRLEHJAXIU-UHFFFAOYSA-N 0.000 claims abstract 6
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 claims abstract 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 2
- 239000011780 sodium chloride Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Abstract
1. Применение композиции, включающей ротиготин и по меньшей мере одну хлоридную соль в концентрации от 1 до 140 ммоль/л, где данная композиция имеет рН от 4 до 6,5, для заправки устройства для ионофореза для лечения болезни Паркинсона. ! 2. Применение по п.1, где концентрация ротиготина составляет по меньшей мере 0,5 мг/мл. ! 3. Применение по п.1 или 2, где концентрация ротиготина составляет от 0,5 до 3 мг/мл. ! 4. Применение по п.1, где хлоридная соль выбрана из NaCl, хлорида триэтиламмония и хлорида трибутиламмония. ! 5. Применение по п.4, где хлоридная соль представляет собой хлорид триэтиламмония или хлорид трибутиламмония. ! 6. Применение по п.1, где концентрация хлоридной соли составляет от 60 до 80 ммоль/л. ! 7. Применение по п.1, где композицию используют в донорной фазе указанного устройства для ионофореза. ! 8. Применение по п.1, где композиция в донорной фазе указанного устройства для ионофореза содержит ротиготин в концентрации от 0,5 до 3 мг/мл и по меньшей мере один из хлорида триэтиламмония и хлорида трибутиламмония в концентрации от 60 до 80 ммоль/л, где рН донорной фазы составляет от 4,5 до 5,5. ! 9. Способ лечения болезни Паркинсона, отличающийся тем, что на кожу нуждающегося в этом пациента прикладывают устройство для ионофореза, которое содержит композицию, включающую ротиготин и по меньшей мере одну хлоридную соль в концентрации от 1 до 140 ммоль/л, где данная композиция имеет рН от 4 до 6,5.
Claims (9)
1. Применение композиции, включающей ротиготин и по меньшей мере одну хлоридную соль в концентрации от 1 до 140 ммоль/л, где данная композиция имеет рН от 4 до 6,5, для заправки устройства для ионофореза для лечения болезни Паркинсона.
2. Применение по п.1, где концентрация ротиготина составляет по меньшей мере 0,5 мг/мл.
3. Применение по п.1 или 2, где концентрация ротиготина составляет от 0,5 до 3 мг/мл.
4. Применение по п.1, где хлоридная соль выбрана из NaCl, хлорида триэтиламмония и хлорида трибутиламмония.
5. Применение по п.4, где хлоридная соль представляет собой хлорид триэтиламмония или хлорид трибутиламмония.
6. Применение по п.1, где концентрация хлоридной соли составляет от 60 до 80 ммоль/л.
7. Применение по п.1, где композицию используют в донорной фазе указанного устройства для ионофореза.
8. Применение по п.1, где композиция в донорной фазе указанного устройства для ионофореза содержит ротиготин в концентрации от 0,5 до 3 мг/мл и по меньшей мере один из хлорида триэтиламмония и хлорида трибутиламмония в концентрации от 60 до 80 ммоль/л, где рН донорной фазы составляет от 4,5 до 5,5.
9. Способ лечения болезни Паркинсона, отличающийся тем, что на кожу нуждающегося в этом пациента прикладывают устройство для ионофореза, которое содержит композицию, включающую ротиготин и по меньшей мере одну хлоридную соль в концентрации от 1 до 140 ммоль/л, где данная композиция имеет рН от 4 до 6,5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026871A EP1426049B1 (en) | 2002-12-02 | 2002-12-02 | Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease |
| EP02026871.0 | 2002-12-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005114749/15A Division RU2339372C2 (ru) | 2002-12-02 | 2003-11-21 | Ионофоретическая доставка ротиготина для лечения болезни паркинсона |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008121750A true RU2008121750A (ru) | 2009-12-20 |
| RU2478383C2 RU2478383C2 (ru) | 2013-04-10 |
Family
ID=32309357
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005114749/15A RU2339372C2 (ru) | 2002-12-02 | 2003-11-21 | Ионофоретическая доставка ротиготина для лечения болезни паркинсона |
| RU2008121750/15A RU2478383C2 (ru) | 2002-12-02 | 2008-05-30 | Ионофоретическая доставка ротиготина для лечения болезни паркинсона |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005114749/15A RU2339372C2 (ru) | 2002-12-02 | 2003-11-21 | Ионофоретическая доставка ротиготина для лечения болезни паркинсона |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7632859B2 (ru) |
| EP (2) | EP1426049B1 (ru) |
| JP (1) | JP2006514937A (ru) |
| KR (1) | KR101168431B1 (ru) |
| CN (1) | CN100333723C (ru) |
| AT (2) | ATE295726T1 (ru) |
| AU (1) | AU2003294718B2 (ru) |
| BR (1) | BR0316947A (ru) |
| CA (1) | CA2505040C (ru) |
| CY (1) | CY1106256T1 (ru) |
| DE (2) | DE60204229T2 (ru) |
| DK (2) | DK1426049T3 (ru) |
| ES (2) | ES2239196T3 (ru) |
| HK (2) | HK1065706A1 (ru) |
| IL (1) | IL168387A (ru) |
| MX (1) | MXPA05005462A (ru) |
| NO (1) | NO335491B1 (ru) |
| NZ (1) | NZ540190A (ru) |
| PL (1) | PL219696B1 (ru) |
| PT (2) | PT1426049E (ru) |
| RU (2) | RU2339372C2 (ru) |
| SI (2) | SI1426049T1 (ru) |
| WO (1) | WO2004050083A1 (ru) |
| ZA (1) | ZA200503750B (ru) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814084B4 (de) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
| US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
| DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
| TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| US8592477B2 (en) * | 2007-11-28 | 2013-11-26 | Ucb Pharma Gmbh | Polymorphic form of rotigotine and process for production |
| DE102008010223A1 (de) | 2008-02-20 | 2009-08-27 | Wash Tec Holding Gmbh | Reinigungsvorrichtung |
| DE202008002377U1 (de) | 2008-02-20 | 2009-06-25 | Washtec Holding Gmbh | Reinigungsvorrichtung |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| DK2515887T3 (en) | 2009-12-22 | 2018-09-17 | Ucb Biopharma Sprl | Polyvinylpyrrolidone to stabilize a solid dispersion of the non-crystalline form of rotigotine |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| CA2916183C (en) | 2013-07-03 | 2022-03-29 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with electronic component |
| CN106456567A (zh) | 2014-05-20 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 在经皮递送系统中调节活性剂释放的方法 |
| CN106456566B (zh) | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
| CA2948221C (en) | 2014-05-20 | 2022-11-22 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| CA3030043C (en) * | 2016-07-21 | 2021-01-19 | Shandong Luye Pharmaceutical Co., Ltd. | Rotigotine behenate, preparation method and use thereof |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5108991A (en) * | 1975-06-19 | 1992-04-28 | Whitby Research, Inc. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US4996226A (en) * | 1984-08-13 | 1991-02-26 | Whitby Research, Inc. | Method and compositions for treatment of parkinsonism syndrome in mammels |
| US5204339A (en) * | 1986-01-31 | 1993-04-20 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
| JPS63502282A (ja) * | 1986-01-31 | 1988-09-01 | ホイットビ−・リサ−チ・インコ−ポレ−テッド | １−置換アザシクロアルカン類より成る組成物とその用法 |
| US4801586A (en) * | 1986-04-23 | 1989-01-31 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agents |
| US5142044A (en) * | 1986-04-23 | 1992-08-25 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
| US5073544A (en) * | 1986-08-15 | 1991-12-17 | Whitby, Inc. | Transdermal compositions of 1-oxohydrocarbyl-substituted azacyclohexanes |
| US4917896A (en) * | 1986-08-15 | 1990-04-17 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agents |
| US4808414A (en) * | 1986-09-29 | 1989-02-28 | Nelson Research & Development Co. | Amide penetration enhancers for transdermal delivery of systemic agents |
| US5118845A (en) * | 1986-09-29 | 1992-06-02 | Whitby Research, Inc. | Penetration enhancer for transdermal delivery of systemic agents |
| US5273757A (en) * | 1987-09-01 | 1993-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Apparatus for the delivery of substances, processes for the production thereof and use thereof |
| US5071645A (en) * | 1987-10-19 | 1991-12-10 | Ppg Industries, Inc. | Process of producing an active agent delivery device |
| EP0317269B1 (en) * | 1987-11-20 | 1992-03-04 | FARMITALIA CARLO ERBA S.r.l. | Antiparkinson ergoline derivatives |
| US4915950A (en) * | 1988-02-12 | 1990-04-10 | Cygnus Research Corporation | Printed transdermal drug delivery device |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5472946A (en) | 1988-04-08 | 1995-12-05 | Peck; James V. | Transdermal penetration enhancers |
| DE3827561C1 (ru) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| US4973468A (en) * | 1989-03-22 | 1990-11-27 | Cygnus Research Corporation | Skin permeation enhancer compositions |
| US5234945A (en) * | 1989-05-09 | 1993-08-10 | Whitby Research, Inc. | Method of producing body weight and food intake using a dopamine D2 receptor agonist |
| US5252335A (en) * | 1989-07-12 | 1993-10-12 | Cygnus Therapeutic Systems | Transdermal administration of lisuride |
| US5091186A (en) * | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
| US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| US5271940A (en) * | 1989-09-14 | 1993-12-21 | Cygnus Therapeutic Systems | Transdermal delivery device having delayed onset |
| US5071875A (en) * | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
| US5151446A (en) * | 1989-09-25 | 1992-09-29 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
| DE3933460A1 (de) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
| EP0507863A4 (en) * | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5147916A (en) * | 1990-02-21 | 1992-09-15 | Dow Corning Corporation | Hot-melt silicone pressure sensitive adhesive composition and related methods and articles |
| US5246997A (en) * | 1990-02-21 | 1993-09-21 | Dow Corning Corporation | Method of making a hot-melt silicone pressure sensitive adhesive-coated substrate |
| US5069909A (en) * | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| US6086905A (en) * | 1991-03-21 | 2000-07-11 | Peck; James V. | Topical compositions useful as skin penetration barriers |
| US5273755A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a polymer-filled microporous membrane to achieve delayed onset |
| US5234690A (en) * | 1991-08-23 | 1993-08-10 | Cygnus Therapeutic Systems | Transdermal drug delivery device using an unfilled microporous membrane to achieve delayed onset |
| US5273756A (en) * | 1991-08-23 | 1993-12-28 | Cygnus Therapeutic Systems | Transdermal drug delivery device using a membrane-protected microporous membrane to achieve delayed onset |
| US5225198A (en) * | 1991-08-27 | 1993-07-06 | Cygnus Therapeutic Systems | Transdermal administration of short or intermediate half-life benzodiazepines |
| AU2514292A (en) * | 1991-08-27 | 1993-03-16 | Cygnus Therapeutic Systems | Transdermal formulations for administering prazosin |
| GB9127306D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| US5308625A (en) * | 1992-09-02 | 1994-05-03 | Cygnus Therapeutic Systems | Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters |
| US5989586A (en) * | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
| DE4301781C2 (de) * | 1993-01-23 | 1995-07-20 | Lohmann Therapie Syst Lts | Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung |
| JPH09503997A (ja) * | 1993-07-08 | 1997-04-22 | シグナス，インコーポレイテッド | モノリシックなマトリックス経皮送達システム |
| US5382596A (en) * | 1993-08-05 | 1995-01-17 | Whitby Research, Inc. | Substituted 2-aminotetralins |
| US5554381A (en) * | 1993-08-09 | 1996-09-10 | Cygnus, Inc. | Low flux matrix system for delivering potent drugs transdermally |
| EP0643981B1 (en) * | 1993-09-22 | 2002-01-09 | Hisamitsu Pharmaceutical Co., Inc. | A matrix for iontophoreses |
| US5771890A (en) * | 1994-06-24 | 1998-06-30 | Cygnus, Inc. | Device and method for sampling of substances using alternating polarity |
| US5670501A (en) * | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| US6024974A (en) * | 1995-01-06 | 2000-02-15 | Noven Pharmaceuticals, Inc. | Composition and methods for transdermal delivery of acid labile drugs |
| US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| US5532278A (en) * | 1995-01-31 | 1996-07-02 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
| FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
| US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| ES2190472T5 (es) * | 1995-06-07 | 2012-03-09 | Ortho-Mcneil Pharmaceutical, Inc. | Parche transdérmico para la administración de 17-deacetil norgestimato, en combinación con un estrógeno. |
| US6316022B1 (en) * | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| US5906830A (en) * | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
| US5902603A (en) * | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
| US5891461A (en) * | 1995-09-14 | 1999-04-06 | Cygnus, Inc. | Transdermal administration of olanzapine |
| US6063398A (en) * | 1995-09-20 | 2000-05-16 | L'oreal | Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent |
| US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
| US5733571A (en) * | 1995-12-08 | 1998-03-31 | Euro-Celtique, S.A. | Transdermal patch for comparative evaluations |
| AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
| US6221627B1 (en) * | 1997-02-24 | 2001-04-24 | Smithkline Beecham Corporation | cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor |
| US5879701A (en) * | 1997-02-28 | 1999-03-09 | Cygnus, Inc. | Transdermal delivery of basic drugs using nonpolar adhesive systems and acidic solubilizing agents |
| US6242572B1 (en) * | 1997-05-13 | 2001-06-05 | Smithkline Beecham Corporation | Human G protein coupled lysophosphatidic acid receptor |
| US6514530B2 (en) * | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE19814083C2 (de) * | 1998-03-30 | 2002-02-07 | Lohmann Therapie Syst Lts | Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen |
| PT1053043E (pt) * | 1998-05-13 | 2002-11-29 | Cygnus Therapeutic Systems | Montagens de recolha para sistemas de amostragem transdermica |
| DE19828273B4 (de) * | 1998-06-25 | 2005-02-24 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren |
| WO2000015108A1 (en) * | 1998-09-17 | 2000-03-23 | Cygnus, Inc. | Press device for a gel/sensor assembly |
| FR2792529B1 (fr) * | 1999-04-26 | 2001-09-28 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines |
| AU5325000A (en) * | 1999-06-05 | 2000-12-28 | David Houze | Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use |
| US6218421B1 (en) * | 1999-07-01 | 2001-04-17 | Smithkline Beecham P.L.C. | Method of promoting smoking cessation |
| DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| DE19938825A1 (de) * | 1999-08-19 | 2001-04-26 | Boehringer Ingelheim Pharma | Wirkstoffkombination mit Clonidin |
| DE19940238A1 (de) * | 1999-08-25 | 2001-03-01 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten |
| ATE245972T1 (de) * | 1999-11-29 | 2003-08-15 | Lohmann Therapie Syst Lts | Transdermale therapeutische systeme mit verbesserter stabilität und ein verfahren zu ihrer herstellung |
| US20020110585A1 (en) * | 1999-11-30 | 2002-08-15 | Godbey Kristin J. | Patch therapeutic agent delivery device having texturized backing |
| US6277875B1 (en) * | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
| DE10060550C1 (de) * | 2000-12-06 | 2002-04-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten |
| US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
| HU227543B1 (en) * | 2001-09-28 | 2011-08-29 | Richter Gedeon Nyrt | N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them |
| NZ537360A (en) * | 2002-06-25 | 2006-09-29 | Acrux Dds Pty Ltd | Transdermal delivery rate control using amorphous pharmaceutical compositions |
| US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
| US8246979B2 (en) | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system for the administration of rotigotine |
| US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
| AU2003284342B2 (en) * | 2002-10-25 | 2009-03-05 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| US9102726B2 (en) * | 2002-12-04 | 2015-08-11 | Argos Therapeutics, Inc. | Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same |
| DE10261696A1 (de) * | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
| US20050032873A1 (en) * | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| CA2554616A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
-
2002
- 2002-12-02 DE DE60204229T patent/DE60204229T2/de not_active Expired - Fee Related
- 2002-12-02 AT AT02026871T patent/ATE295726T1/de not_active IP Right Cessation
- 2002-12-02 EP EP02026871A patent/EP1426049B1/en not_active Expired - Lifetime
- 2002-12-02 SI SI200230125T patent/SI1426049T1/xx unknown
- 2002-12-02 ES ES02026871T patent/ES2239196T3/es not_active Expired - Lifetime
- 2002-12-02 PT PT02026871T patent/PT1426049E/pt unknown
- 2002-12-02 DK DK02026871T patent/DK1426049T3/da active
-
2003
- 2003-11-17 US US10/713,424 patent/US7632859B2/en not_active Expired - Fee Related
- 2003-11-21 RU RU2005114749/15A patent/RU2339372C2/ru not_active IP Right Cessation
- 2003-11-21 BR BR0316947-2A patent/BR0316947A/pt not_active IP Right Cessation
- 2003-11-21 AT AT03785652T patent/ATE342719T1/de active
- 2003-11-21 WO PCT/EP2003/013111 patent/WO2004050083A1/en active IP Right Grant
- 2003-11-21 EP EP03785652A patent/EP1567146B1/en not_active Expired - Lifetime
- 2003-11-21 PT PT03785652T patent/PT1567146E/pt unknown
- 2003-11-21 DE DE60309203T patent/DE60309203T2/de not_active Expired - Lifetime
- 2003-11-21 PL PL377575A patent/PL219696B1/pl unknown
- 2003-11-21 ES ES03785652T patent/ES2273062T3/es not_active Expired - Lifetime
- 2003-11-21 SI SI200330539T patent/SI1567146T1/sl unknown
- 2003-11-21 AU AU2003294718A patent/AU2003294718B2/en not_active Ceased
- 2003-11-21 CA CA2505040A patent/CA2505040C/en not_active Expired - Fee Related
- 2003-11-21 CN CNB2003801047255A patent/CN100333723C/zh not_active Expired - Fee Related
- 2003-11-21 DK DK03785652T patent/DK1567146T3/da active
- 2003-11-21 MX MXPA05005462A patent/MXPA05005462A/es active IP Right Grant
- 2003-11-21 JP JP2004556165A patent/JP2006514937A/ja active Pending
- 2003-11-21 KR KR1020057009547A patent/KR101168431B1/ko not_active IP Right Cessation
- 2003-11-21 NZ NZ540190A patent/NZ540190A/en not_active IP Right Cessation
-
2004
- 2004-11-01 HK HK04108542A patent/HK1065706A1/xx not_active IP Right Cessation
-
2005
- 2005-05-04 IL IL168387A patent/IL168387A/en not_active IP Right Cessation
- 2005-05-10 ZA ZA200503750A patent/ZA200503750B/en unknown
- 2005-06-16 NO NO20052959A patent/NO335491B1/no not_active IP Right Cessation
- 2005-12-08 HK HK05111244A patent/HK1079108A1/xx not_active IP Right Cessation
-
2006
- 2006-11-23 CY CY20061101696T patent/CY1106256T1/el unknown
-
2008
- 2008-05-30 RU RU2008121750/15A patent/RU2478383C2/ru not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008121750A (ru) | Ионофоретическая доставка ротиготина для лечения болезни паркинсона | |
| CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
| DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| DE122009000036I2 (de) | Verwendung von Dapoxetin, ein selektiver Serotonin Aufnahme Inhibitor mit schnellem Wirkungseintritt, zur Behandlung von sexueller Dysfunktion | |
| DE60112248D1 (de) | Allzweck -medikament und -wärmebehandlungssystem | |
| HRP20080146T3 (en) | Preoperative treatment of post operative pain | |
| RU2003113987A (ru) | Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны | |
| DE602004025040D1 (de) | Den blutzuckerspiegel bei diabetes mellitus regulierendes tetrapeptid | |
| RU2004113429A (ru) | Способ лечения зрительного утомления у пользователей компьютерами | |
| DE60213968D1 (de) | Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen | |
| Diedrich et al. | Idiopathic scoliosis. A 25-YEAR FOLLOW-UP | |
| RU2002109173A (ru) | Способ лечения дистрофических заболеваний сетчатой оболочки глаза | |
| RU2001103672A (ru) | Способ лечения больных артериальной гипертензией | |
| RU2003112906A (ru) | Способ лечения акантолической пузырчатки | |
| EA199800737A1 (ru) | Способ лечения заболеваний, связанных с образованием конкрементов | |
| RU2002109128A (ru) | Способ лечения нейроциркуляторной дистонии | |
| RU2000115826A (ru) | Способ лечения наркологической зависимости |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171122 |